Yaş Tip Yaşa Bağlı Makula Dejenerasyonunda İntravitreal Ranibizumab Tedavi Sonuçlarımız

Pur po se: To evaluate the efficacy and safety of intravitreal ranibizumab injection for exudative age-related macular degeneration.\udMa te ri al and Met hod: In this study, we included forty-eight eyes of 43 age-related macular degeneration patients followed for at\udleast twelve months. Mean age was 73.65±8.93 years and mean follow-up time was 14.2 months. All patients received three consecutive\udmonthly intravitreal ranibizumab injections and then were followed up with clinical examination and optic coherence tomography\udmonthly. Re-injection was executed as needed.\udRe sults: Twenty patients were male (46.5%) and twenty-three patients were female (53.5%). The average number of ranibizumab\udinjection was 3.7 (3-7) per eye. Twenty-six lesions (54.2%) were classic (predominantly and minimally) and twenty-two (45.8%) were\udoccult. Mean best-corrected visual acuity was 46.8 letters with ETDRS chart at the initial examination and 55.5 letters at twelfth\udmonth. Mean central foveal thickness decreased from 320 microns to 269 microns. There was a statistically significant improvement\udin visual acuity and central foveal thickness. On the other hand, this improvement was not significant between lesion types. During\udfollow-up, there were no systemic or serious ocular complications determined.\udDis cus si on: Intravitreal ranibizumab injection is safe and effective, both anatomically and functionally, for age-related macular\uddegeneration. (Turk J Ophthalmol 2012; 42: 25-